Paratek Pharmaceuticals, Inc.
75 Park Plaza
About Paratek Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria.
Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017.
Board of Directors Michael F. Bigham Chairman of the Board and Chief Executive Officer
Evan Loh, MD Director and President, Chief Medical Officer
Thomas J. Dietz, Ph.D. Director
Timothy Franson, M.D., Director
Richard Lim Director
Kristine Peterson Director
Robert Radie Director
Jeffrey Stein, Ph.D. Director
Last Updated: 04-23-02
114 articles with Paratek Pharmaceuticals, Inc.
MMS Submission Support for Paratek Pharmaceuticals Garners FDA Approval and Successful MAA Filing of NUZYRA™ (Omadacycline)
MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today their expert support to Paratek Pharmaceuticals, Inc.
Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced the acceptance of the submission to the European Medicines Agency (EMA) of the Marketing Authorization Application (MAA) for omadacycline.
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced that the U.S. Food and Drug Administration (FDA) has approved NUZYRA™ (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).
To be launched in U.S. by Almirall SA
Paratek Pharmaceuticals, Inc. today announced that on September 28, 2018, the Company granted stock options and restricted stock units to two new employees of the Company.
Shares of Paratek Pharmaceuticals are climbing in pre-market trading after the company announced a U.S. Food and Drug Administration advisory committee voted overwhelmingly in favor of the company’s intravenous and oral treatments for acute bacterial skin and skin structure infections (ABSSSI).
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...
Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections
Paratek Pharmaceuticals, Inc. announced that an analysis of microbiology data from OASIS-2, its second Phase 3 study of omadacycline in acute skin infections, found that once-daily monotherapy with oral omadacycline is effective in treating frequently isolated pathogens associated with skin infections, including resistant Staphylococcus aureus (MRSA).
Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID
Paratek Pharmaceuticals, Inc. presented an analysis of data from the Company’s Phase 3 OPTIC study of omadacycline vs. moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP) using the European Medicines Agency (EMA) guidance for approval of new treatments for CABP.
Here’s a look at eight biopharma companies with upcoming catalysts.
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018
The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website.
Paratek Completes Submission of NDAs to the FDA for Oral and Intravenous Omadacycline for Pneumon...
2/5/2018The FDA has previously granted omadacycline both Qualified Infectious Disease Product and Fast Track designation for these indications.
The stock options are to acquire, in the aggregate, 85,850 shares of the Company’s common stock at a per share exercise price of $15.25.
All of the shares to be sold in the offering are to be sold by Paratek.
In addition, Paratek has granted the underwriter a 30-day option to purchase up to an additional 480,769 shares of its common stock.
Paratek has initiated the rolling submission of a NDA to the FDA for the indications of ABSSSI and CABP and is on track to submit the final components during the first quarter of 2018.
These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan.
MMS announced today that it was selected by Paratek Pharma to support the development of its U.S. NDAs for omadacycline.
Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018
Paratek reported a net loss of $21.3 million, or ($0.77) per share, for the quarter ended September 30, 2017 compared to a net loss of $23.6 million, or ($1.04) per share, for the same period in 2016.
New antibiotic development seems to go through cycles and many large companies have stayed away from antibiotics or abandoned efforts, despite a growing need for new antibiotics.